Promising Clinical Results and Robust Financial Position Warrant a Buy Rating for TScan Therapeutics

TD Cowen analyst Tara Bancroft has maintained their bullish stance on TCRX stock, giving a Buy rating today.

Tara Bancroft’s rating is based on the notable clinical outcomes and future potential of TScan Therapeutics’ lead assets, TSC-100 and TSC-101. The therapies have shown impressive results with a 100% relapse-free rate at 10 months, which is a significant improvement over the 22% relapse rate at 6 months typically observed with transplant. Such a strong performance anticipates a favorable 12-month data readout, expected in the second half of the year, which could bolster confidence in the therapies’ long-term efficacy and support the initiation of a pivotal trial by 2025.
Additionally, TScan’s solid tumor program is progressing with six therapies in clinical trials, with initial data also anticipated in the latter half of the year. The financial position of the company, with cash reserves expected to last into the fourth quarter of 2026, provides a stable runway through the commencement of a liquid tumor pivotal trial. Bancroft’s assessment likely considers the combination of these clinical and financial factors, which together present a strong case for a Buy rating for TScan Therapeutics’ stock.

In another report released today, Needham also maintained a Buy rating on the stock with a $11.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

TScan Therapeutics (TCRX) Company Description:

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.